{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"}],"units":"Participants"}],"description":"Assess the safety and tolerability of idelalisib","groups":[{"description":"After the screening procedures confirms eligibility to participate in the research study. Treatment will be administered on an outpatient basis.\n\n\\-- Idelalisib (GS-11-01) orally, predetermined dose twice daily per cycle for up to 6 cycles. After this initial 6 month period, for Cycles 7 and beyond, Idelalisib will be administered once a day until disease progression.\n\nGS-1101","id":"OG000","title":"GS-1101"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Participants were followed for the duration of therapy, a median of one cycle, for up to 3 cycles.","title":"Percentage of Participants With Adverse Events","type":"SECONDARY","unitOfMeasure":"percentage of participants with AEs"}